Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Has Consensus Target Price of $49.50

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have received a consensus recommendation of “Buy” from the thirteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $49.50.

Several equities analysts recently commented on STRO shares. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a research note on Thursday, August 13th. Wall Street Zen raised shares of Sutro Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Stifel Nicolaus set a $48.00 price objective on Sutro Biopharma and gave the company a “buy” rating in a research note on Friday, August 7th. Wedbush reiterated an “outperform” rating and issued a $60.00 target price on shares of Sutro Biopharma in a report on Thursday, October 15th. Finally, Mizuho upgraded shares of Sutro Biopharma to a “strong-buy” rating in a research report on Wednesday, September 16th.

Institutional Investors Weigh In On Sutro Biopharma

Several institutional investors have recently bought and sold shares of the stock. Merck & Co. Inc. bought a new position in shares of Sutro Biopharma during the second quarter valued at about $9,042,053. Seven Fleet Capital Management LP bought a new stake in shares of Sutro Biopharma in the second quarter valued at $5,283,000. Perceptive Advisors LLC purchased a new position in shares of Sutro Biopharma during the 1st quarter valued at $17,818,000. Affinity Asset Advisors LLC increased its holdings in Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock worth $26,642,000 after acquiring an additional 321,137 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Sutro Biopharma in the 2nd quarter worth about $1,373,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $9.94 on Thursday. Sutro Biopharma has a fifty-two week low of $7.15 and a fifty-two week high of $43.85. The company has a market cap of $164.82 million, a price-to-earnings ratio of -0.83 and a beta of 1.56. The stock has a fifty day moving average price of $14.70 and a 200-day moving average price of $22.73.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) EPS for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The company had revenue of $9.84 million during the quarter, compared to analyst estimates of $11.96 million. Research analysts predict that Sutro Biopharma will post -8.12 EPS for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.